A Phase 1/2 interventional study of Alcestobart and Tislelizumab in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, sponsored by BeiGene. Active, not recruiting at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.
Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is one of 8 that started in 2023, is one of 4 in phase 1/2, reaches primary completion later than 5 of the 18 other live ones, and was the 11th registered.
6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Austria, Germany
Ages 18+
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–80
Memorial Sloan Kettering Cancer Center · Sites in United States, Nigeria
Ages 18+
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 1
First in 2021; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 33 across the 27 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing tislelizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06520683Phase 3Sun Yat-sen UniversityAdjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer | 2027-11-01 |
| NCT06356597Jing-yuan Fang, MD, Ph. DTislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial | 2026-12-30 |
| NCT07025850Fudan UniversityEfficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | 2027-01-01 |
| NCT07453875Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityLDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies testing tislelizumab in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received alcestobart low dose, tislelizumab, bevacizumab and capecitabine until disease progression, unacceptable toxicity, or withdrawal of consent.
Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
Participants received alcestobart medium dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
Participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
PD-L1 (programmed cell death protein ligand-1)-positive participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
PD-L1-positive participants received alcestobart high dose, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Alcestobart · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
PD-L1-positive participants received bevacizumab and fluoropyrimidine in combination with leucovorin or levoleucovorin (LV) until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
PD-L1-negative participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
PD-L1-negative participants received bevacizumab and fluoropyrimidine in combination with LV until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)
Administered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks
Also known as: LBL-007
Administered intravenously at a dose of either 200 mg once every 3 weeks or 300 mg once every 4 weeks.
Also known as: BGB-A317
Administered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks.
Fluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks.
Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C
PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.
Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and C
DOR is defined as the time from the first determination of an objective confirmed response after randomization until the first documentation of disease progression or death, whichever comes first.
Time frame: From first documented response until disease progression or death (maximum follow-up time for DOR was 4.2 months)
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E
PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first.
Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months)
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E
ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months))
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E
DOR, defined as the time from the first confirmed objective response after randomization until the first documentation of disease progression or death, whichever comes first.
Time frame: From first documented response until disease progression or death (maximum follow-up time for DOR was 2.8 months)
Phase 2: Number of Participants With Treatment-emergent AEs and SAEs
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment in Phase 2 was 10.9 months
The study began in January 2023 and was conducted in 3 countries. The study consisted of Phase 1b and Phase 2. Phase 1b was completed as planned. On 20 December 2024, the sponsor decided to close enrollment in Phase 2 before achieving the planned sample size. Participants who continued to benefit from the study drugs were permitted to continue treatment in an Extended treatment Period which is currently ongoing.
| Milestone | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose+ Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 13 | 6 | 18 | 9 | 16 | 22 | 23 |
| Treated | 6 | 13 | 6 | 18 | 9 | 14 | 22 | 22 |
| Completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 12 | 6 | 18 | 9 | 16 | 22 | 23 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 0 | 3 | 1 | 4 |
| Withdrew: Study terminated by sponsor | 3 | 2 | 2 | 6 | 5 | 5 | 8 | 5 |
| Withdrew: Death | 1 | 3 | 1 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Continuing in extended treatment period | 1 | 6 | 1 | 10 | 2 | 8 | 10 | 12 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine |
|---|---|---|---|
| Treatment emergent adverse event | 6 | 13 | 6 |
| Serious adverse event | 3 | 8 | 3 |
PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.
| months | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C | NA (3.5 to NA) | 4.4 (2.1 to NA) |
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C | 5.6 (0.1 to 27.3) | 0.0 (0.0 to 20.6) |
DOR is defined as the time from the first determination of an objective confirmed response after randomization until the first documentation of disease progression or death, whichever comes first.
| months | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and C | NA (NA to NA) | — |
PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first.
| months | Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E | 6.5 (3.9 to NA) | 10.4 (4.1 to NA) |
ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E | 0.0 (0.0 to 15.4) | 4.3 (0.1 to 21.9) |
DOR, defined as the time from the first confirmed objective response after randomization until the first documentation of disease progression or death, whichever comes first.
| months | Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|
| Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E | — | NA (NA to NA) |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab + Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|---|---|---|
| Treatment Emergent adverse event | 17 | 9 | 13 | 22 | 22 |
| Serious adverse event | 3 | 1 | 3 | 7 | 4 |
Collected over Mortality was collected up to the end of the main part of the study, maximum time on study was 22.9 months. Adverse events were assessed from first dose of study drug to 30 days after last dose, maximum time on treatment was 16.2 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | 3/13 (23.1%) | 8/13 (61.5%) | 13/13 (100%) |
| Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | 0/18 (0%) | 3/18 (16.7%) | 17/18 (94.4%) |
| Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | 0/16 (0%) | 3/14 (21.4%) | 12/14 (85.7%) |
| Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ Fluoropyrimidine | 2/22 (9.1%) | 7/22 (31.8%) | 21/22 (95.5%) |
| Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | 2/23 (8.7%) | 4/22 (18.2%) | 22/22 (100%) |
| Event | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|---|---|---|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 1/6 | 0/13 | 0/6 | 0/18 | 1/9 | 0/14 | 0/22 | 1/22 |
| Jaundice cholestaticHepatobiliary disorders | 1/6 | 0/13 | 0/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| PneumoniaInfections and infestations | 0/6 | 0/13 | 1/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/6 | 0/13 | 1/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| KetoacidosisMetabolism and nutrition disorders | 0/6 | 0/13 | 1/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| Cerebral infarctionNervous system disorders | 1/6 | 0/13 | 0/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/13 | 1/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 1/6 | 0/13 | 0/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/6 | 0/13 | 0/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| ColitisGastrointestinal disorders | 0/6 | 2/13 | 0/6 | 0/18 | 0/9 | 0/14 | 0/22 | 0/22 |
| Event | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine |
|---|---|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/6 | 1/13 | 5/6 | 3/18 | 3/9 | 1/14 | 5/22 | 5/22 |
| HyperthyroidismEndocrine disorders | 0/6 | 0/13 | 4/6 | 2/18 | 0/9 | 0/14 | 2/22 | 0/22 |
| Alanine aminotransferase increasedInvestigations | 4/6 | 2/13 | 3/6 | 3/18 | 0/9 | 1/14 | 1/22 | 1/22 |
| AnaemiaBlood and lymphatic system disorders | 3/6 | 2/13 | 1/6 | 1/18 | 1/9 | 2/14 | 2/22 | 5/22 |
| HypothyroidismEndocrine disorders | 1/6 | 5/13 | 3/6 | 5/18 | 0/9 | 0/14 | 4/22 | 0/22 |
| StomatitisGastrointestinal disorders | 1/6 | 3/13 | 3/6 | 0/18 | 1/9 | 1/14 | 2/22 | 3/22 |
| Aspartate aminotransferase increasedInvestigations | 2/6 | 2/13 | 3/6 | 3/18 | 0/9 | 1/14 | 2/22 | 3/22 |
| White blood cell count decreasedInvestigations | 3/6 | 1/13 | 3/6 | 1/18 | 1/9 | 1/14 | 2/22 | 1/22 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 | 2/13 | 1/6 | 4/18 | 0/9 | 1/14 | 4/22 | 2/22 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 5/13 | 1/6 | 5/18 | 0/9 | 1/14 | 2/22 | 3/22 |
113 participants were enrolled in the study, 110 participants received study drugs, 2 participants in Arm C and 1 participant in Arm E were randomized but not treated due to withdrawal by participant
| Age, Continuous(years) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.5 ± 7.66 | 57.8 ± 13.27 | 53.7 ± 11.62 | 54.6 ± 11.16 | 63.0 ± 9.75 | 56.3 ± 14.18 | 61.1 ± 11.24 | 58.1 ± 10.42 | 58.0 ± 11.51 |
| Sex: Female, Male(Participants) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 8 | 2 | 8 | 5 | 8 | 7 | 11 | 53 |
| Male | 2 | 5 | 4 | 10 | 4 | 8 | 15 | 12 | 60 |
| Race/Ethnicity, Customized(Participants) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 6 | 10 | 6 | 16 | 9 | 14 | 22 | 22 | 105 |
| Hispanic or Latino | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 4 |
| Not reported | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 5 | 5 | 5 | 12 | 6 | 7 | 14 | 15 | 69 |
| White | 1 | 6 | 1 | 3 | 3 | 7 | 5 | 6 | 32 |
| Other | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Not reported | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 4 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 5 |
| Region of Enrollment(Participants) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 1 | 6 | 1 | 5 | 2 | 5 | 5 | 4 | 29 |
| China | 4 | 4 | 3 | 13 | 5 | 7 | 14 | 16 | 66 |
| Australia | 1 | 3 | 2 | 0 | 2 | 4 | 3 | 3 | 18 |
| Liver Metastases: Yes/No(Participants) | Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 12 | 4 | 13 | 6 | 13 | 14 | 18 | 85 |
| No | 1 | 1 | 2 | 5 | 3 | 3 | 8 | 5 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Jan 2023 to primary completion in May 2025, 27 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 27 months is below that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alcestobart · Tislelizumab